Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:14:53 EDT Thu 10 Sep 2026
Enter Symbol
or Name
USA
CA



Q:CYDY - CYTODYN INC - https://www.cytodyn.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYDY - Qnot subscribed0.19-0.0098-4.92,408.64493070.203  0.2032  0.18440.397  0.182915:59:45Sep 0115 min RT 2¢

Recent Trades - Last 10 of 307
Time ETExPriceChangeVolume
15:59:45Q0.19-0.009812,000
15:59:17Q0.19-0.009812,000
15:58:50Q0.19-0.00984,000
15:58:49Q0.19-0.009817,000
15:58:33Q0.1895-0.01035,000
15:58:33Q0.1895-0.0103245
15:58:20Q0.19-0.009812,000
15:58:00Q0.189-0.010810,000
15:57:53Q0.189-0.010815,000
15:57:52Q0.19-0.009812,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-01 08:30U:CYDYNews ReleaseCytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
2026-06-11 08:30U:CYDYNews ReleaseCytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
2026-06-04 08:00U:CYDYNews ReleaseNatera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
2026-06-03 08:30U:CYDYNews ReleasePlatform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
2026-05-15 08:30U:CYDYNews ReleaseCytoDyn to Present at the LD Micro Invitational XVI
2026-05-11 08:30U:CYDYNews ReleaseCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
2026-04-27 08:30U:CYDYNews ReleaseCytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
2026-04-23 08:30U:CYDYNews ReleaseCytoDyn to Host Investor Webcast
2026-04-22 08:30U:CYDYNews ReleaseCytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
2026-04-21 16:10U:CYDYNews ReleaseCytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
2026-04-20 08:30U:CYDYNews ReleaseCytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
2026-04-14 08:30U:CYDYNews ReleaseCytoDyn to Present at the AACR Annual Meeting 2026
2026-03-24 08:30U:CYDYNews ReleaseCytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
2026-03-05 08:30U:CYDYNews ReleaseCytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
2026-02-20 08:30U:CYDYNews ReleaseCytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
2026-01-27 08:30U:CYDYNews ReleaseCytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
2025-12-16 08:30U:CYDYNews ReleaseDecember 2025 Letter to Shareholders
2025-12-08 08:30U:CYDYNews ReleaseCytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
2025-12-01 08:30U:CYDYNews ReleaseCytoDyn Announces Resolution of Class Action Lawsuit
2025-11-24 08:30U:CYDYNews ReleaseCytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium